Summit Therapeutics reports a wider second quarter 2026 loss but strengthens its balance sheet ahead of a key ivonescimab PDUFA date.

Summit Therapeutics reported a GAAP net loss of $0.28 per share for the second quarter of 2026 with no revenue, as the company increased spending on clinical development for its lead candidate, ivonescimab. The company significantly bolstered its financial position by raising capital during the quarter.

Key Highlights

• In an updated analysis from the Phase III HARMONi study, ivonescimab showed a consistent overall survival benefit with a hazard ratio of 0.76 in both Western and Asian patient subgroups.
• The company ended the quarter with $690.7 million in cash and investments after raising $230.8 million in gross proceeds through its at-the-market (ATM) facility.
• Key upcoming catalysts include the PDUFA goal action date of November 14, 2026, for ivonescimab in EGFR-mutated NSCLC and the primary analysis from the HARMONi-3 study's squamous cohort, expected in the second half of 2026.